Biocon Gets US FDA Nod for Breast Cancer Biosimilar Pebrilzo
Biocon said Pebrilzo, a biosimilar of Perjeta, is its fifth oncology biosimilar to win US FDA approval.
Key Takeaways
- Biocon said the US FDA has approved Pebrilzo (pertuzumab-qcay), a biosimilar of Perjeta (pertuzumab).
- Pebrilzo is used to treat HER2-positive breast cancer.
- Biocon said it is the company's fifth oncology biosimilar to get US FDA approval.
- Its other US oncology biosimilars are Ogivri, Jobevne, Fulphila and Aukelso.
- Biocon said a settlement with Genentech sets the earliest licensed US launch in the third quarter of calendar 2028.
Table of Contents 7 sections
- Biocon's Pebrilzo approval at a glance
- How Biocon's Pebrilzo is used in HER2-positive breast cancer
- Pebrilzo joins four other Biocon cancer biosimilars in the US
- Shreehas Tambe on what Pebrilzo adds to Biocon's cancer portfolio
- When Biocon says Pebrilzo can reach US patients
- Where Biocon's oncology portfolio stands after the Pebrilzo approval
- FAQs
Biocon Limited said on Monday, November 16, 2026, that the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). Pebrilzo is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The Bengaluru-headquartered company shared the news in a stock exchange filing.
Biocon said Pebrilzo is its fifth oncology biosimilar to receive US FDA approval. The company also said it has signed a global settlement and licence agreement with Genentech that secures the earliest licensed launch date for Pebrilzo in the United States in the third quarter of calendar year 2028.
Biocon's Pebrilzo approval at a glance
| Detail | Value |
|---|---|
| Company | Biocon Limited (BSE: 532523, NSE: BIOCON) |
| Headquarters | Bengaluru, India |
| Product | Pebrilzo (pertuzumab-qcay) |
| Reference product | Perjeta (pertuzumab) |
| Used for | HER2-positive breast cancer |
| Approved by | US Food and Drug Administration |
| Announced | November 16, 2026 |
| Place in portfolio | Biocon's fifth oncology biosimilar with US FDA approval |
| Earliest licensed US launch | Third quarter of calendar 2028, under a settlement with Genentech, Biocon said |
How Biocon's Pebrilzo is used in HER2-positive breast cancer
According to Biocon, Pebrilzo is approved for use with trastuzumab and docetaxel to treat adults with HER2-positive metastatic breast cancer who have not received earlier anti-HER2 therapy or chemotherapy for metastatic disease. It is also approved for use with trastuzumab and chemotherapy for adults with HER2-positive early breast cancer, as a neoadjuvant treatment and as an adjuvant treatment for patients at high risk of recurrence.
Biocon said the approval was based on a package of structural and functional analytical characterisation, analytical similarity and comparative clinical pharmacokinetic data. The company said this data showed Pebrilzo is highly similar to Perjeta, with no clinically meaningful differences in quality, safety, efficacy and immunogenicity.
Pebrilzo joins four other Biocon cancer biosimilars in the US
Biocon's oncology portfolio in the US already includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb) and Aukelso (denosumab-kyqq). The company said its oncology pipeline also includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, covering HER2-directed therapy and immuno-oncology.
| When | What happened |
|---|---|
| September 2026 | The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gives a positive opinion recommending marketing authorisation for Biocon's pertuzumab biosimilar, under the brand name Pebrilzo, in Europe |
| November 16, 2026 | Biocon announces US FDA approval of Pebrilzo (pertuzumab-qcay) |
| Third quarter of 2028 | Earliest licensed US launch date for Pebrilzo under the Genentech settlement, as stated by Biocon |
Shreehas Tambe on what Pebrilzo adds to Biocon's cancer portfolio
Biocon said Shreehas Tambe, its CEO and Managing Director, called the US FDA approval an important step in expanding access to high-quality biosimilars for patients with HER2-positive breast cancer. He said Pebrilzo, Biocon's fifth oncology biosimilar approved in the US, strengthens its cancer portfolio and its aim of expanding access to affordable biologic medicines.
When Biocon says Pebrilzo can reach US patients
Biocon said its global settlement and licence agreement with Genentech secures the earliest licensed launch date for Pebrilzo in the United States in the third quarter of calendar year 2028.
Where Biocon's oncology portfolio stands after the Pebrilzo approval
With Pebrilzo, Biocon now has five oncology biosimilars approved by the US FDA, alongside Ogivri, Jobevne, Fulphila and Aukelso. The approval follows the positive CHMP opinion for Pebrilzo in Europe in September, and Biocon said the earliest licensed US launch of the product is in the third quarter of calendar year 2028.
More news
Frequently Asked Questions
What is Pebrilzo?
What did Biocon announce on November 16, 2026?
What is Pebrilzo a biosimilar of?
How does Biocon's Pebrilzo work?
How is Pebrilzo used in metastatic breast cancer?
Is Pebrilzo approved for early breast cancer?
How many oncology biosimilars does Biocon have approved in the US?
What are Biocon's other oncology biosimilars in the US?
When will Biocon launch Pebrilzo in the US?
How did Biocon show Pebrilzo is similar to Perjeta?
Who is the CEO of Biocon?
What other biosimilars is Biocon developing in oncology?
More in Business
Muthoot FinCorp Q2 Profit Doubles to Rs 779 Crore
Muthoot FinCorp's Q2 FY27 profit rose to Rs 779 crore from Rs 388.31 crore a year earlier.
Adani Wind Starts Making 91.2 Metre Turbine Blades in Mundra
Adani Wind has started making 91.2 metre wind turbine blades at its plant in Mundra, Gujarat.
Pace Digitek Wins About Rs 2,691 Crore Order From NTPC Green
Pace Digitek has won a Rs 2,691.30 crore battery storage order from NTPC Green Energy in Gujarat.
